Press Release

Equa®, Exforge® and Afinitor® provide new treatment options for unmet medical needs

Three major approvals for innovative medicines to treat serious and life-threatening diseases affecting millions of Japanese patients

Approvals follow six product launches in 2009, reinforcing the strong presence of Novartis in Japan, the company's second-largest pharmaceutical market


Basel, January 20, 2010 - Patients in Japan will benefit from the approval of three new Novartis medicines - Equa® (vildagliptin), marketed as Galvus® in the European Union, for the treatment of type 2 diabetes, Exforge® (valsartan/amlodipine) for high blood pressure, and Afinitor® (everolimus) for advanced kidney cancer. These approvals reinforce the strong commitment of Novartis to helping patients in Japan, the company's second-largest pharmaceutical market.

"It is a significant achievement to secure the approval of three such important new medicines for the benefit of Japanese patients," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division. "These approvals, which follow six launches last year, mean we continue to quickly introduce innovative medicines to treat serious and life-threatening diseases affecting millions of Japanese patients and their families."

Equa has been approved in Japan for the treatment of type 2 diabetes, as monotherapy or in combination with a sulfonylurea. As a DPP-4 inhibitor, Equa works by targeting the dysfunction in the pancreatic islets that causes high blood sugar levels in people with type 2 diabetes.

Equa has been approved for doses of 50 mg twice daily, or 50 mg once daily, depending on the needs of the individual patient[1]. Patients treated with Equa 50 mg twice daily demonstrated an average reduction in HbA1c - a marker of blood glucose level - of 1.2% compared to placebo[2], which would bring half of them within the maximum HbA1c value of 6.5% recommended by the Japan Diabetes Society[2]. Equa was shown to be well-tolerated with a favorable profile in terms of hypoglycemia and bodyweight[2].

An estimated 7 million people in Japan have type 2 diabetes[3] and approximately 70% of patients are still not meeting their HbA1c goals on their current medications[4]. When left untreated or inadequately controlled, type 2 diabetes can lead to heart and kidney disease, blindness, and vascular or neurologic problems[5].

Exforge has been approved in Japan as a single-pill combination of two treatments for high blood pressure: Diovan® (valsartan), the number one selling hypertension medication worldwide[6], and amlodipine, the world's most prescribed calcium channel blocker[6]. Exforge has been shown to be effective across all grades of high blood pressure[7], [8], with placebo-like tolerability[9]. As many as nine out of 10 Exforge patients reach their blood pressure goal[10], with drops of up to 43 mmHg reported in patients with particularly elevated blood pressure[8].

High blood pressure affects an estimated 40 million people in Japan; nearly a third of the population[11]. With approximately 70% of patients not reaching their blood pressure treatment goal[12], there is a growing need for effective and convenient single-pill combination therapies. High blood pressure is one of the most important treatable risk factors for cardiovascular disease - the number one cause of death worldwide[13].

Afinitor (everolimus) in tablet form has been approved in Japan for the treatment of patients with non-resectable, metastatic renal cell carcinoma (advanced kidney cancer). Each year, more than 10,000 people in Japan are diagnosed with kidney cancer[14].

A once-daily therapy, Afinitor provides continuous inhibition of the mTOR protein, a central regulator of tumor cell division and blood vessel growth in cancer cells. Afinitor is the first mTOR inhibitor approved to treat advanced kidney cancer patients in Japan.

Japan took part in the pivotal, international, Phase III trial for Afinitor on which the approval was based. The trial, RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily), included patients from 14 trial sites across Japan. RECORD-1 showed that Afinitor, when compared with placebo, more than doubled the median time without tumor growth or death in patients with advanced kidney cancer whose disease progressed following earlier VEGF-targeted therapy (4.9 vs. 1.9 months, p<0.0001) [15]. Prior to Afinitor, no other therapy had been studied in a Phase III trial in this patient population where there is an important unmet medical need.

This regulatory decision marks the third major approval for Afinitor in less than a year, following approvals in the European Union and United States[15],[16]. Afinitor is also being studied worldwide in multiple tumor types, including in Japanese patients with pancreatic neuroendocrine tumors, gastric cancer, lymphoma and breast cancer.

As an investigational compound, the safety and efficacy profile of everolimus has not yet been established in these cancer and tumor types. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will ever become commercially available for these cancer and tumor types anywhere in the world. In Japan, everolimus is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart transplant recipients.

Novartis Pharma K.K. is a Japanese affiliate of Novartis AG, Switzerland. For more information on NPKK, please visit http://www.novartis.co.jp/.

For more information:
http://www.novartis.com/newsroom/media-releases/en/2010/1375090.shtml